Fusion

Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
Tuesday, February 27, 2024
Oncology, Mental Health, Health, Infectious Diseases, Neurology, Pharmaceutical, Biotechnology, NSCLC, TED, Blood pressure, Cervical cancer, Psoriasis, Cetuximab, Infection, New Drug Application, SCLC, MAA, National Medical Products Administration, PMA, CIDP, NTRK, FDA, Nivolumab, Food, GEJ, Shanda, Schizophrenia, PDUFA, CRC, Bristol Myers Squibb, BMS, ADP, Safety, Mirati, TPS, Disease, HKT, Patient, Clinical trial, METIS, Fusion, Pancreatic cancer, NDA, NMPA, Pharmaceutical industry

The New Drug Application (NDA) that Zai Lab submitted to the NMPA for this indication is under priority review.

Key Points: 
  • The New Drug Application (NDA) that Zai Lab submitted to the NMPA for this indication is under priority review.
  • Zai Lab has joined the global Phase 3 FORTITUDE-102 study of bemarituzumab in combination with nivolumab and chemotherapy in first-line gastric or GEJ cancer in Greater China.
  • Zai Lab to submit an sBLA to the NMPA for efgartigimod SC in CIDP in the first half of 2024.
  • Zai Lab to complete patient enrollment in the China bridging study in schizophrenia in the fourth quarter of 2024.

Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting

Retrieved on: 
Tuesday, March 5, 2024
Fusion, PSMA, AACR, Safety, Patient, Clinical trial, Poster

HAMILTON, ON and BOSTON, March 5, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that interim efficacy and safety data from the Phase 2 TATCIST clinical trial evaluating FPI-2265 in patients with metastatic castration-resistant prostate cancer (mCRPC) has been selected for a clinical trial poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California.

Key Points: 
  • HAMILTON, ON and BOSTON, March 5, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that interim efficacy and safety data from the Phase 2 TATCIST clinical trial evaluating FPI-2265 in patients with metastatic castration-resistant prostate cancer (mCRPC) has been selected for a clinical trial poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California.
  • Presentation at AACR Annual Meeting 2024:
    Title: Preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
    Session Date and Time: Tuesday April 9, 2024, 9:00 a.m – 12:30 p.m. PT
    The poster will be available on Fusion's website following the presentation.
  • For more details about the AACR Annual Meeting, please visit: https://www.aacr.org/meeting/aacr-annual-meeting-2024/ .

Fusion Academy Set to Open First Broward County Location

Retrieved on: 
Tuesday, March 5, 2024
Fusion, Education, Fusion Academy, Social, Music, Student, Parent, Suite, Tutoring

GRAND RAPIDS, Mich., March 5, 2024 /PRNewswire/ -- Fusion Academy, the world's most personalized school with one-to-one classes to match students' pace and preference, continues its expansion in Florida with its fourth location in the state and first in Broward County. Located at 880 Southwest 145th Ave., Suite 100, the new school is set to open June 10 with a grand opening event slated later in the season.

Key Points: 
  • GRAND RAPIDS, Mich., March 5, 2024 /PRNewswire/ -- Fusion Academy , the world's most personalized school with one-to-one classes to match students' pace and preference, continues its expansion in Florida with its fourth location in the state and first in Broward County.
  • Located at 880 Southwest 145th Ave., Suite 100 , the new school is set to open June 10 with a grand opening event slated later in the season.
  • Along with assisting local grade 6-12 students to reach their academic potential, Fusion Academy wants to restructure and balance a busy life schedule.
  • For more information about the new Pembroke Pines location or to learn more about Fusion Academy's philosophies toward personalized education, please call 754-223-1228 or visit our website .

Perimeter Medical Imaging AI Reports Its Proprietary Artificial Intelligence Algorithm + OCT Identified 96.8% of Positive Breast Cancer Margins in Newly Published Peer Reviewed Study

Retrieved on: 
Thursday, February 29, 2024
Breast cancer, Perimeter, Baylor University, Neoplasm, Fusion, OTC, PINK, Principal investigator, Data, Breast, Medicine, Medical imaging

2023; 13(12):2340. https://doi.org/10.3390/life13122340

Key Points: 
  • 2023; 13(12):2340. https://doi.org/10.3390/life13122340
    From a clinical perspective, the deep learning model showed high levels of sensitivity and specificity, accurately identifying 96.8% of pathology-positive margins.
  • These results highlight the clinical viability of AI-enhanced margin visualization using WF-OCT in breast cancer surgery and its potential to decrease reoperation rates due to residual tumors.
  • Adrian Mendes, Perimeter's Chief Executive Officer, stated, "We have a training dataset of several million proprietary images of both cancerous and healthy tissue captured with our OCT imaging technology.
  • Perimeter intends to conduct a planned interim analysis in the second quarter of 2024, with study completion anticipated by the end of 2024.

Baicells Announces its Fusion RAN Network Platform for Mobile Operators and Service Providers

Retrieved on: 
Monday, February 26, 2024
ENB, Flexible, ROI, LTE, CPE, BBU, Investment, Fusion, GSM, RRU, GNB, RAN, Mobile World Congress, Element, Software, Innovation, Mobile phone

DALLAS, Feb. 26, 2024 /PRNewswire/ -- Baicells Technologies, a global provider of turnkey 4G LTE and 5G NR solutions for operators and the enterprise, has announced the launch of its Fusion RAN platform. The platform is a scalable and highly flexible RAN solution that allows service providers of all types offer multiple wireless services (2G, 4G, 5G) from a single networking platform. Fusion RAN delivers on the Baicells mission to connect more with less.

Key Points: 
  • Highly Flexible and Innovative RAN Solution offers ability to deliver 2G, 4G, and 5G services from single network platform.
  • DALLAS, Feb. 26, 2024 /PRNewswire/ -- Baicells Technologies , a global provider of turnkey 4G LTE and 5G NR solutions for operators and the enterprise, has announced the launch of its Fusion RAN platform.
  • The platform is a scalable and highly flexible RAN solution that allows service providers of all types offer multiple wireless services (2G, 4G, 5G) from a single networking platform.
  • Fusion RAN delivers on the Baicells mission to connect more with less.

DSI to sell CloudNC's CAM Assist AI software to North American CAM CAD programmers

Retrieved on: 
Tuesday, February 20, 2024
Cloud, CNC, Martin, AI, Fusion, Learning curve, DSI, CAD, Autodesk, Lockheed, Software, Partnership, Machine shop

DSI, the US's largest Solution Provider for Autodesk's Fusion, will sell CloudNC's CAM Assist, the world's first AI solution for CNC machine programming, to North American precision CNC workshops.

Key Points: 
  • DSI, the US's largest Solution Provider for Autodesk's Fusion, will sell CloudNC's CAM Assist, the world's first AI solution for CNC machine programming, to North American precision CNC workshops.
  • DSI, a manufacturing software specialist and the US's largest reseller for Autodesk's Fusion, already has relationships with thousands of North American CAM CAD programmers.
  • Its new reseller partnership with CloudNC will immediately make CAM Assist available to its active, engaged user base.
  • In seconds, CAM Assist drafts the code required to instruct a CNC machine how to make it, within the user's existing CAM platform.

Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy

Retrieved on: 
Friday, February 16, 2024
European Commission, Fusion, Cancer, Food, PSMA, Patent, Civil service commission, Heidelberg University, Patient, Joint Research Centre, Radiation, Pharmaceutical industry

HAMILTON, ON and BOSTON, Feb. 16, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has entered into an exclusive worldwide license agreement with Heidelberg University and Euratom represented by the European Commission, Joint Research Centre (together, the "Licensors"). The license agreement grants Fusion exclusive worldwide rights to utilize, develop, manufacture and commercialize compounds covered by the patent, which includes 225Ac-PSMA I&T ("FPI-2265") for the treatment of prostate specific membrane antigen (PSMA)-expressing cancers. In addition, Fusion and the Licensors have signed an agreement to settle the parties' dispute related to an inter partes review ("IPR") of a U.S. patent owned by the Licensors which was instituted in August 2023 by the United States Patent and Trademark Board.

Key Points: 
  • HAMILTON, ON and BOSTON, Feb. 16, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has entered into an exclusive worldwide license agreement with Heidelberg University and Euratom represented by the European Commission, Joint Research Centre (together, the "Licensors").
  • The license agreement grants Fusion exclusive worldwide rights to utilize, develop, manufacture and commercialize compounds covered by the patent, which includes 225Ac-PSMA I&T ("FPI-2265") for the treatment of prostate specific membrane antigen (PSMA)-expressing cancers.
  • Fusion President and Chief Business Officer Mohit Rawat said, "We are pleased to enter into this exclusive license agreement with Heidelberg University and Euratom for their existing patent as we progress FPI-2265, the most advanced actinium-based PSMA targeted radiotherapy currently in development.
  • Under the terms of the license agreement, Fusion will pay the Licensors an aggregate upfront fee of €1.0 million, in addition to certain regulatory milestones upon potential approval and low single-digit royalties on future net sales of applicable products.

Fusion Fuel Receives Notification of IPCEI Approval from European Commission for 630 MW HEVO-Portugal Project

Retrieved on: 
Friday, February 16, 2024
European Commission, European Investment Bank, Fusion, BofA Securities, European, Commercial, Civil service commission, Port of Sines, Port, Renewable energy

SABUGO, Portugal, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Fusion Fuel (NASDAQ: HTOO) (the “Company”) is pleased to announce that it has received notification from the European Commission that the Company’s HEVO-Portugal project was among 33 selected for approval under the Important Projects of Common European Interest (“IPCEI”) Hy2Infra program.

Key Points: 
  • SABUGO, Portugal, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Fusion Fuel (NASDAQ: HTOO) (the “Company”) is pleased to announce that it has received notification from the European Commission that the Company’s HEVO-Portugal project was among 33 selected for approval under the Important Projects of Common European Interest (“IPCEI”) Hy2Infra program.
  • The €650 million, 630 MW project is to be developed in Sines, Portugal, and would produce 62,000 tonnes of green hydrogen per annum.
  • The IPCEI approval positions Fusion Fuel and its partners to commence funding negotiations with the relevant government stakeholders, as well as with the European Investment Bank, which has committed to providing financing and advisory support to those projects selected for public funding.
  • Frederico Figueira de Chaves, CEO of Fusion Fuel, stated, “This is a game changing achievement for Fusion Fuel, solidifying our position amongst the leading companies in the green hydrogen industry.

China Automotive Software Business Models and Suppliers' Layout Research Report 2023 - Introduction of Large AI Models into Vehicles has Become a Main Trend

Retrieved on: 
Thursday, February 15, 2024
Cloud, Google Cloud, ETAS, SkyOS, Socs, AI, Research, Fusion, Partnership, Supply chain, IAA, Original equipment manufacturer, NRE, NIO, ChatGPT, Conference, OS, Human, GPT, Software as a service, Mercedes-Benz, Qualcomm, EEA, Apple, Vector, IP, Li Auto, Volkswagen, Mind, Microsoft, Artificial intelligence, CARIAD, Travel, Software

DUBLIN, Feb. 15, 2024 /PRNewswire/ -- The "Automotive Software Business Models and Suppliers' Layout Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 15, 2024 /PRNewswire/ -- The "Automotive Software Business Models and Suppliers' Layout Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.
  • In terms of business forms, software providers are now engaged in custom software development and design, technical services, software licensing/authorization and system integration.
  • The introduction of large AI models into vehicles has become a main trend this year.
  • Moreover as the application of large AI models in vehicles speeds up, suppliers also create the foundation model pre-integrated supply mode.

Diesel Laptops Announces VIN Decoder Integration with Karmak

Retrieved on: 
Thursday, February 15, 2024
Fusion, Partnership, Database, API, Satellite navigation device

This collaboration signifies a pivotal advancement in vehicle data management, enabling seamless integration of Diesel Laptops' VIN Decoding service into the Karmak Fusion Business System, free of additional charge to users.

Key Points: 
  • This collaboration signifies a pivotal advancement in vehicle data management, enabling seamless integration of Diesel Laptops' VIN Decoding service into the Karmak Fusion Business System, free of additional charge to users.
  • Effective January 31, 2024, users of Karmak Fusion, version 3.66.36 and beyond, will gain direct access to Diesel Laptops' comprehensive VIN Decoding service.
  • This partnership reaffirms Diesel Laptops' and Karmak's shared commitment to enhancing the user experience through innovative solutions.
  • Karmak Fusion users can look forward to a vastly improved VIN decoding process, ensuring greater consistency and reliability in vehicle data management.